Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.65 |
| ▸ | GLA | P06280 | 1/20 | 0.65 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.65 |
| ▸ | MAOA | P21397 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | RAD52 | P43351 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29868545 | 1.00 | CYP1A2 (0.72) | CYP1A2CYP3A4CYP2D6CYP2C19HSD17B10 | |
| SCHEMBL4103388 | 0.89 | CYP1A2 (0.76) | CYP1A2CYP3A4CYP2D6CYP2C19HSD17B10 | |
| SCHEMBL23112133 | 0.87 | CYP1A2 (0.61) | CYP1A2CYP3A4CYP2D6CYP2C19HSD17B10 | |
| SCHEMBL18932187 | 0.87 | MAOA (0.68) | CYP1A2CYP3A4CYP2D6CYP2C19HSD17B10 | |
| SCHEMBL10737635 | 0.87 | CYP1A2 (0.68) | CYP1A2CYP3A4CYP2D6CYP2C19HSD17B10 | |
| Hydrochloric Acid SCHEMBL3452579 | 0.85 | CYP1A2 (0.67) | CYP1A2CYP3A4CYP2D6CYP2C19HSD17B10 | |
| SCHEMBL17381541 | 0.84 | KDM4E (0.70) | CYP1A2CYP3A4CYP2D6CYP2C19HSD17B10 | |
| SCHEMBL10707749 | 0.84 | CYP1A2 (0.74) | CYP1A2CYP3A4CYP2D6CYP2C19HSD17B10 | |
| SCHEMBL4103661 | 0.84 | HSD17B10 (0.68) | CYP1A2CYP3A4CYP2D6CYP2C19HSD17B10 | |
| SCHEMBL4109030 | 0.84 | HSD17B10 (0.68) | CYP1A2CYP3A4CYP2D6CYP2C19HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| CN-107531703-B | Dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory diseases | 加拉帕戈斯股份有限公司 | 2020-09-01 | — | — | CN | disclosed |
| EP-3286191-B1 | NOVEL DIHYDROPYRIDOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2020-07-29 | — | — | EP | disclosed |
| EP-3286191-B1 | NOVEL DIHYDROPYRIDOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2020-07-29 | — | — | EP | disclosed |
| US-10568879-B2 | Dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2020-02-25 | — | — | US | disclosed |
| US-10568879-B2 | Dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2020-02-25 | — | — | US | disclosed |
| US-10155259-B2 | FSH receptor antagonists | MERCK SHARP & DOHME B.V. (NL) | 2018-12-18 | — | — | US | disclosed |
| EP-3286191-A1 | NOVEL DIHYDROPYRIDOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Galapagos NV (BE) | 2018-02-28 | — | — | EP | disclosed |
| CN-107531703-A | For treating the new dihydro pyrido isobioquin group and its pharmaceutical composition of diseases associated with inflammation | 加拉帕戈斯股份有限公司 | 2018-01-02 | — | — | CN | disclosed |
| EP-2763986-B1 | FSH RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (NL) | 2017-06-07 | — | — | EP | disclosed |
| US-9127007-B2 | FSH receptor antagonists | MERCK SHARP & DOHME B.V. (NL) | 2015-09-08 | — | — | US | disclosed |
| US-20140350043-A1 | FSH RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME B.V. (NL) | 2014-11-27 | — | — | US | disclosed |
| US-20140350043-A1 | FSH RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME B.V. (NL) | 2014-11-27 | — | — | US | disclosed |
| US-20140350043-A1 | FSH RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME B.V. (NL) | 2014-11-27 | — | — | US | disclosed |
| EP-2763986-A1 | FSH RECEPTOR ANTAGONISTS | Merck Sharp & Dohme B.V. (NL) | 2014-08-13 | — | — | EP | disclosed |
| WO-2013041458-A1 | FSH RECEPTOR ANTAGONISTS | MSD OSS B.V. (NL) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013041458-A1 | FSH RECEPTOR ANTAGONISTS | MSD OSS B.V. (NL) | 2013-03-28 | — | — | WO | disclosed |
| US-20120258957-A1 | HETEROCYCLIC DERIVATIVES | MSD OSS B.V. (NL) | 2012-10-11 | — | — | US | disclosed |
| EP-2504316-A1 | HETEROCYLIC COMPOUNDS AS ANTAGONISTS OF THE OREXIN RECEPTORS | MSD Oss B.V. (NL) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011061318-A1 | HETEROCYLIC COMPOUNDS AS ANTAGONISTS OF THE OREXIN RECEPTORS | N.V. ORGANON (NL) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10568879-B2 | Dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GPR84, GPR88, GPR65 | CYP1A2 777/4885CYP3A4 1428/4885CYP2D6 1354/4885 |
| US-20140350043-A1 | FSH RECEPTOR ANTAGONISTS | FSHR, GNRHR, LHCGR | CYP1A2 2703/4885CYP3A4 3553/4885CYP2D6 2410/4885 |
| US-20230133132-A1 | NAMPT MODULATORS | NAMPT, MC4R, SIRT1 | CYP1A2 2420/4885CYP3A4 2794/4885CYP2D6 2623/4885 |
| US-20120258957-A1 | HETEROCYCLIC DERIVATIVES | HCRTR2, HCRTR1, NPY5R | CYP1A2 230/4885CYP3A4 326/4885CYP2D6 234/4885 |
| US-10155259-B2 | FSH receptor antagonists | FSHR, GNRHR, LHCGR | CYP1A2 3152/4885CYP3A4 4001/4885CYP2D6 2785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.